SCHEMBL3701581

SCHEMBL3701581

O=C(NCCC(O)CCO)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
SLC1A3 P43003 1/20 0.57
SLC1A1 P43005 1/20 0.57
HTT P42858 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.53
TGM2 P21980 1/20 0.51
KEAP1 Q14145 2/20 0.50
NFE2L2 Q16236 2/20 0.50
FOLH1 Q04609 2/20 0.49
MAPT P10636 1/20 0.49
CTRB1 P17538 2/20 0.48
DPP8 Q6V1X1 1/20 0.47
DPP7 Q9UHL4 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KCNA5 P22460 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL590358 0.90 LMNA (0.61) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL735078 0.90 LMNA (0.61) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL734427 0.90 LMNA (0.61) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL3697605 0.89 TGM2 (0.60) LMNASMN1; SMN2HTTTGM2KEAP1
SCHEMBL3694578 0.89 TGM2 (0.60) LMNASMN1; SMN2HTTTGM2KEAP1
SCHEMBL14146574 0.87 SLC1A3 (0.60) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL18375320 0.87 LMNA (0.58) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL16691249 0.87 LMNA (0.54) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL4923251 0.87 LMNA (0.54) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL16691163 0.87 LMNA (0.54) LMNASMN1; SMN2SLC1A3SLC1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081949-B1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE GE HEALTHCARE DHARMACON INC (US) 2014-12-10 EP disclosed
US-8809514-B2 Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference GE HEALTHCARE DHARMACON, INC. (US) 2014-08-19 US disclosed
US-8501706-B2 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON, INC. (US) 2013-08-06 US disclosed
EP-2064223-B1 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON INC (US) 2013-04-24 EP disclosed
US-20120322855-A1 Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference DHARMACON, INC. (US) 2012-12-20 US disclosed
US-8252755-B2 Duplex oligonucleotide complexes and methods for gene silencing by RNA interference DHARMACON, INC. (US) 2012-08-28 US disclosed
US-20100093085-A1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC (US) 2010-04-15 US disclosed
EP-2081949-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-07-29 EP disclosed
EP-2064223-A2 DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE Dharmacon, Inc. (US) 2009-06-03 EP disclosed
US-20080085869-A1 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism DHARMACON, INC. (US) 2008-04-10 US disclosed
WO-2008036825-A2 DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed
WO-2008036841-A2 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE DHARMACON, INC. (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093085-A1 TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE SNRPE, DCLRE1B, RNASE1 LMNA 1804/4885SMN1; SMN2 492/4885SLC1A3 3192/4885
US-20120322855-A1 Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference SNRPE, AGO2, DCLRE1B LMNA 2348/4885SMN1; SMN2 520/4885SLC1A3 3769/4885
US-20080085869-A1 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism SRRT, SNRPE, SSBP1 LMNA 1556/4885SMN1; SMN2 119/4885SLC1A3 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.